Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients
- 628 Downloads
We retrospectively investigated increases in large granular lymphocytes (LGL) in peripheral blood during dasatinib treatment in 25 chronic myelogenous leukemia patients. Fifteen of 25 patients (60 %) showed an increase in LGL. All 15 of these patients also showed an increase in NK cells, and 11 showed an increase in CD8+ T cells. High frequencies of clonal rearrangements of TCR-β, -γ, and -δ genes were observed in LGL (+) patients, and at lower frequencies in LGL (−) patients as well. Clinical responses were favorable for all. With respect to their newly obtained complete molecular response after dasatinib treatment, LGL (+) patients showed higher response rates than did LGL (−) patients. In contrast, pleural effusions were more commonly observed in LGL (+) patients (60 %) than in LGL (−) patients (20 %). LGL counts significantly increased at 2 h after oral intake of dasatinib in all 25 patients. This was not observed in treatment with imatinib or nilotinib. Cytomegalovirus (CMV) C7-HRP tests were negative in all patients. Serum CMV-IgM antibodies were positive in only 2 of 25 patients without symptom of infection. Thus, LGL lymphocytosis during dasatinib treatment may be correlated with favorable molecular response, and with increased incidence of pleural effusions. In the clinical setting, CMV reactivation appears uncommon.
KeywordsCML LGL Dasatinib TCR CMV
Conflict of interest
The authors declare that they have no conflict of interest.
- 13.Powers JJ, Dubovsky JA, Epling-Burnette PK, Moscinski L, Zhang L, Mustjoki S, et al. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma. 2011;52:668–79.PubMedCrossRefGoogle Scholar
- 16.Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010;116:377–86.PubMedCrossRefGoogle Scholar
- 17.Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540–6.PubMedCrossRefGoogle Scholar
- 19.van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257–317.PubMedCrossRefGoogle Scholar
- 23.Silla LM, Pincus SM, Locker JD, Glover J, Elder EM, Donnenberg AD, et al. Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/ABL-positive targets. Br J Haematol. 1996;93:375–85.PubMedCrossRefGoogle Scholar
- 32.Jayson GC, Parker GJ, Mullamitha S, Valle JW, Saunders M, Broughton L, et al. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab′, leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol. 2005;23:973–81.PubMedCrossRefGoogle Scholar
- 33.Imagawa J, Tanaka H, Matsumoto K, Morita K, Harada Y, Harada H (2012) A sharp fluctuation in peripheral blood cells shortly after dasatinib administration. Int J Hematol (in press)Google Scholar
- 34.Mustjoki S, Rousselot P, Jalkanen S, Kreutzman A, Melo T, Lahesmaa A-M, et al. Dasatinib induce a rapid, dose-controllable mobilization of cytotoxic lymphocytosis: A novel immunomodulatory effect associated with prolonged therapy responses in advanced leukemia. #1204, The 52th ASH Annual Meeting and Exposition. 2010.Google Scholar
- 35.Al-Ameri A, Kantarjian H, Borthakur G, Bahceci E, Szatrowski T, Damokosh A, et al. Opportunistic infection are uncommon with dasatinib in patients with chronic myeloid leukemia in chronic phase (CP-CML). #1120, The 51th ASH Annual Meeting and Exposition. 2009.Google Scholar